Nanotherapy with CBD and Low-Dose Naltrexone
APH-1501 is an investigational, intramuscular extended‑release therapy that pairs low‑dose naltrexone (LDN) with cannabidiol (CBD) to target the two key drivers of recurrence—opioid reward and stress‑craving. Built on Aphios’ SFS‑PNS™ nanoencapsulation platform, the formulation is designed to improve CBD bioavailability, stabilize both agents, and release them gradually over time to support adherence without relying on opioid agonists.
Quick Facts
- Type: Investigational therapy
- Modality: CBD + LDN (dual-agent)
- Route: Intramuscular injection
- Form: Extended-release injectable
- Platform: SFS-PNS™ (SuperFluids™ Polymer Nanospheres)
- Status: Pre-approval; not available for clinical
The Need—A Non-Addictive Alternative
With nearly 100,000 opioid-related deaths annually in the U.S., there is a pressing need for effective, long-acting, non-opioid treatments for opioid use disorder (OUD). While methadone, buprenorphine, and Vivitrol® are vital options, many patients face challenges including adherence, side effects, stigma, and relapse risk.
The APH-1501 Solution
APH-1501 is a non-opioid, extended-release OUD treatment that combines low-dose naltrexone (LDN) and CBD in a single intramuscular injection. Designed as an alternative to methadone and buprenorphine, APH-1501 aims to support opioid relapse prevention and reduce cravings and stress responses associated with OUD.

Key Highlights
- Dual-agent approach: CBD + LDN for complementary mechanisms in OUD
- Intramuscular, extended-release therapy for sustained exposure
- Non-opioid, non-agonist strategy for opioid addiction
- Biodegradable polymer nanospheres using the SFS-PNS™ platform
How It Works—Dual-Action Mechanism
- LDN (low-dose naltrexone): Transiently blocks opioid receptors, helping reduce reward from illicit opioid use and support relapse prevention.
- CBD (cannabidiol): Modulates pathways linked to craving, stress, and anxiety (including serotonergic activity such as 5-HT1A), offering a cannabinoid-based OUD therapy without opioid agonism.
Together, these non-opioid modalities seek to address both the biological reinforcement of opioid use and the stress-craving cycle that drives recurrence.
How the SFS-PNS™ Delivery Platform Works
SFS‑PNS™ (SuperFluids™ Polymer Nanospheres) encapsulates active ingredients in biodegradable polymer nanospheres using a solvent‑free process. The platform is designed to improve CBD bioavailability, protect actives from degradation, and enable a controlled, extended release after intramuscular injection.
- Improved CBD bioavailability and stability via polymer nanospheres
- Sustained release for long‑term therapeutic action
- Biodegradable, solvent‑free delivery using Aphios SuperFluids™ Polymer Nanospheres (SFS‑PNS™) platform
- Supports precise, extended delivery in a single injectable
Key Benefits at a Glance
- Non-opioid therapy for opioid use disorder using antagonist and cannabinoid pathways
- Intramuscular extended-release formulation to support adherence
- Potential reduction in cravings, anxiety, and stress associated with OUD
- Novel addiction treatment biotech enabled by SFS-PNS™ nanoencapsulation
Note: APH-1501 is an investigational therapy and is not approved for clinical use. This product has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease.
Market Opportunity
The global OUD treatment market is projected to exceed $16 billion, with significant unmet needs for safe, effective, non-opioid options that improve persistence and outcomes over time.
Frequently Asked Questions
APH-1501 combines low-dose naltrexone (an opioid receptor antagonist) with cannabidiol (CBD) in an extended-release, intramuscular formulation—supporting OUD treatment without opioid agonists.
Aphios’ SuperFluids™ Polymer Nanospheres (SFS-PNS™) platform enables sustained release and improved CBD stability, designed to maintain therapeutic levels over time and reduce dosing frequency.
APH-1501 is an investigational therapy and is not approved for clinical use. Availability depends on ongoing development and future regulatory review.
Unlike opioid agonist therapies such as methadone or buprenorphine, APH-1501 uses a non-opioid approach—LDN to block euphoric effects and CBD to modulate stress and craving pathways.
Invest in Aphios Pharma
Regulation Crowdfunding (Reg CF)
Invest in Aphios Pharma through Reg CF and support next-generation CNS therapies. Purchase common units until July 11, 2025.
Regulation D (Accredited Investors)
We are also raising $30M under Regulation D for IND-enabling studies, scale-up, and Phase 2 trials. Contact us for our investor presentation.
Join Our Mailing List
Subscribe to receive updates on our latest clinical research, investment opportunities, and product developments.